KeyBanc downgraded Health Catalyst to Sector Weight from Overweight without a price target. The analyst sees potential risks emerging to hospital end markets in the form of potentially decelerating utilization as measured by KeyBanc’s proprietary credit card data. In addition, increased record hiring levels at compounded levels of wage inflation are likely compress margins and spend for solutions, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $15 from $17 at Piper Sandler
- Health Catalyst price target lowered to $11 from $12 at Canaccord
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst sees FY24 revenue $304M-$312M, consensus $324.49M
- Health Catalyst sees Q1 revenue $72.5M-$76.5M, consensus $78.99M